Anti-tumor activity of a TBK1/IKBKE inhibitor in combination with a MEK inhibitor in KRAS mutant colorectal and non-small cell lung cancer models. (December 2016) - Stinson, S.; He, J.; Hollenback, D.; Jia, J.; Kaplan, J.; Venkataramani, C.; Babusis, D.; Guevara, F.; Nelson, T.; Cavanaugh, J.; Asahina, H.; Ray, A.; et al.